Drug Pricing of Domestic Anti-PD-L1 Antibody Adebrelimab: Cost-Effectiveness Analysis of the First-Line ES-SCLC Treatment in China

Zhou D, Dong X, Zhou Z, Liu Q

Risk Management and Healthcare Policy 2023, 16:2521-2529

Published Date: 22 November 2023